| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | -0.15 | 2e-05 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.17 | 3e-05 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.16 | 3e-05 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | -0.14 | 3e-05 |
| mRNA | AZD6482 | CTRPv2 | pan-cancer | AAC | 0.17 | 3e-05 |
| mRNA | ABT-263 | CTRPv2 | pan-cancer | AAC | -0.16 | 3e-05 |
| mRNA | SN-38 | GDSC1000 | pan-cancer | AAC | -0.15 | 5e-05 |
| mRNA | ZSTK474 | CTRPv2 | pan-cancer | AAC | 0.17 | 5e-05 |
| mRNA | RDEA119 | GDSC1000 | pan-cancer | AAC | -0.13 | 7e-05 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.15 | 8e-05 |